Black Swift Group LLC Increases Stock Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Black Swift Group LLC lifted its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 98.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 14,300 shares of the company’s stock after purchasing an additional 7,100 shares during the quarter. Black Swift Group LLC’s holdings in Establishment Labs were worth $659,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ESTA. Bamco Inc. NY grew its position in Establishment Labs by 13.6% in the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after buying an additional 58,611 shares during the last quarter. Mudita Advisors LLP grew its position in Establishment Labs by 19.0% in the 3rd quarter. Mudita Advisors LLP now owns 354,801 shares of the company’s stock valued at $15,352,000 after buying an additional 56,700 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Establishment Labs in the 4th quarter valued at $12,898,000. Redmile Group LLC grew its position in Establishment Labs by 22.9% in the 3rd quarter. Redmile Group LLC now owns 261,803 shares of the company’s stock valued at $11,328,000 after buying an additional 48,779 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its position in Establishment Labs by 2.5% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 248,435 shares of the company’s stock valued at $10,750,000 after buying an additional 6,050 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $43.60 on Thursday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -16.90 and a beta of 0.95. Establishment Labs Holdings Inc. has a one year low of $28.16 and a one year high of $60.12. The company’s fifty day moving average is $37.55 and its two-hundred day moving average is $41.37. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analysts’ expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.